Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 12, Number 5—May 2006
THEME ISSUE
Tuberculosis Special Section

Research

Mycobacterium tuberculosis and Rifampin Resistance, United Kingdom

I-Ching Sam*1, Francis Drobniewski*Comments to Author , Philip More*, Melanie Kemp*, and Timothy Brown*
Author affiliations: *Health Protection Agency, London, United Kingdom

Main Article

Table 6

Results of LiPA in detecting rifampin resistance in clinical specimens in which MTBC was correctly identified and cultured, stratified by history of antituberculous treatment*

Treatment history No. positive/no. tested (%)
Concordance Sensitivity Specificity PPV NPV
Current or within 3 mo 46/48 (95.8) 8/10 (80.0) 38/38 (100) 8/8 (100) 38/40 (95.0)
>3 mo ago 41/42 (97.6) 7/7 (100) 34/35 (97.1) 7/8 (87.5) 34/34 (100)
None stated 689/691 (99.7) 23/23 (100) 666/668 (99.7) 23/25 (92.0) 666/666 (100)

*LiPA, line probe assay; MTBC, Mycobacterium tuberculosis complex; AFB, acid-fast bacilli; PPV, positive predictive value; NPV, negative predictive value.

Main Article

1Current affiliation: University of Malaya, Kuala Lumpur, Malaysia

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO